A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma

We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started to markedly increase 3 days after the patient's second dose of bortezomib was administered, when fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Youngwoon, Kim, Ka Young, Lee, Su Hyun, Chung, Yoon Yung, Yahng, Seung-Ah, Lee, Sung-Eun, Park, Gyeongsin, Min, Chang-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422711/
https://www.ncbi.nlm.nih.gov/pubmed/22916049
http://dx.doi.org/10.4110/in.2012.12.3.126
_version_ 1782241055492538368
author Kim, Youngwoon
Kim, Ka Young
Lee, Su Hyun
Chung, Yoon Yung
Yahng, Seung-Ah
Lee, Sung-Eun
Park, Gyeongsin
Min, Chang-Ki
author_facet Kim, Youngwoon
Kim, Ka Young
Lee, Su Hyun
Chung, Yoon Yung
Yahng, Seung-Ah
Lee, Sung-Eun
Park, Gyeongsin
Min, Chang-Ki
author_sort Kim, Youngwoon
collection PubMed
description We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started to markedly increase 3 days after the patient's second dose of bortezomib was administered, when free kappa light chains were noticeably reduced in the serum. After discontinuation of bortezomib, liver enzymes recovered gradually to baseline. Then, the patient was started on a thalidomide-containing regimen, which he was able to tolerate well. The patient achieved complete remission prior to autologous stem cell transplantation (ASCT). The patient underwent ASCT without occurrence of further liver toxicity.
format Online
Article
Text
id pubmed-3422711
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Korean Association of Immunologists
record_format MEDLINE/PubMed
spelling pubmed-34227112012-08-22 A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma Kim, Youngwoon Kim, Ka Young Lee, Su Hyun Chung, Yoon Yung Yahng, Seung-Ah Lee, Sung-Eun Park, Gyeongsin Min, Chang-Ki Immune Netw Case Report We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started to markedly increase 3 days after the patient's second dose of bortezomib was administered, when free kappa light chains were noticeably reduced in the serum. After discontinuation of bortezomib, liver enzymes recovered gradually to baseline. Then, the patient was started on a thalidomide-containing regimen, which he was able to tolerate well. The patient achieved complete remission prior to autologous stem cell transplantation (ASCT). The patient underwent ASCT without occurrence of further liver toxicity. The Korean Association of Immunologists 2012-06 2012-06-30 /pmc/articles/PMC3422711/ /pubmed/22916049 http://dx.doi.org/10.4110/in.2012.12.3.126 Text en Copyright © 2012 The Korean Association of Immunologists http://creativecommons.org/licenses/by-nc/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kim, Youngwoon
Kim, Ka Young
Lee, Su Hyun
Chung, Yoon Yung
Yahng, Seung-Ah
Lee, Sung-Eun
Park, Gyeongsin
Min, Chang-Ki
A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
title A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
title_full A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
title_fullStr A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
title_full_unstemmed A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
title_short A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
title_sort case of drug-induced hepatitis due to bortezomib in multiple myeloma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422711/
https://www.ncbi.nlm.nih.gov/pubmed/22916049
http://dx.doi.org/10.4110/in.2012.12.3.126
work_keys_str_mv AT kimyoungwoon acaseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT kimkayoung acaseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT leesuhyun acaseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT chungyoonyung acaseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT yahngseungah acaseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT leesungeun acaseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT parkgyeongsin acaseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT minchangki acaseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT kimyoungwoon caseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT kimkayoung caseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT leesuhyun caseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT chungyoonyung caseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT yahngseungah caseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT leesungeun caseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT parkgyeongsin caseofdruginducedhepatitisduetobortezomibinmultiplemyeloma
AT minchangki caseofdruginducedhepatitisduetobortezomibinmultiplemyeloma

Ejemplares similares